Finance

Lists
Why is DMRA down 2.04%?
Dive Deeper
DMRA:NASDAQ
Damora Therapeutics Inc
$21.60
-2.04%
(-0.45) 1D
$21.60
0.00% (0.00)
After hours
Closed: Nov 13, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for DMRA...
Open
$22.11
High
$22.39
Low
$21.10
Mkt. cap
1.34B
Avg. vol.
493.70K
Volume
475.27K
52-wk high
$34.89
52-wk low
$16.50
EPS
-$137.44
Beta
1.52
Shares outstanding
61.90M
No. of employees
7
Open
$22.11
High
$22.39
Low
$21.10
Mkt. cap
1.34B
Avg. vol.
493.70K
Volume
475.27K
52-wk high
$34.89
52-wk low
$16.50
EPS
-$137.44
Beta
1.52
Shares outstanding
61.90M
No. of employees
7
News stories
From web sources and news partners
About Damora Therapeutics Inc
CEO-
Employees7
Founded2011
HeadquartersWaltham, Massachusetts, United States
SectorHealth Care
IndustryBiotechnology
Websitedamoratx.com
Analyst ratings
Based on 6 analysts giving stock ratings to DMRA in the past 3 months
Strong buy
Buy
6
Hold
0
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for DMRA in the last 3 months.
Highest
Current $21.60
$59.00 (+173.15%)
Average
$46.67 (+116.06%)
Lowest
$40.00 (+85.19%)
Analyst
Recommendation
Action
Price target
Projected
Date
Bradley Canino
Guggenheim
Buy
Maintained
$59.00
+173.1%
11/05/2026
David Nierengarten
Wedbush
Buy
Maintained
$40.00
+85.2%
11/05/2026
Andrew Berens
Leerink Partners
Buy
Maintained
$51.00
+136.1%
11/05/2026
Brian Abrahams
RBC Capital
Buy
Maintained
$40.00
+85.2%
11/04/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
$45.00
+108.3%
11/05/2026
Sam Slutsky
LifeSci Capital
Buy
Maintained
$45.00
+108.3%
09/18/2026
Akash Tewari
Jefferies
Buy
Maintained
$50.00
+131.5%
08/11/2026
Marc Frahm
TD Cowen
Buy
Maintained
-
-
08/10/2026
Gavin Clark-Gartner
Evercore ISI
Buy
Initiated
$46.00
+113%
03/25/2026
Michael Yee
UBS
Buy
Initiated
$45.00
+108.3%
02/17/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
23.32M
23.78M
25.54M
25.48M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.07M
7.03M
9.45M
11.39M
Operating expense
27.39M
30.81M
34.99M
36.86M
Total operating expenses
27.39M
30.81M
34.99M
36.86M
Operating income
-27.39M
-30.81M
-34.99M
-36.86M
Other non operating income
-
-
-
-
EBT including unusual items
-200.69M
-27.74M
-30.92M
-31.99M
EBT excluding unusual items
-26.38M
-27.74M
-30.92M
-32.74M
Income tax expense
44.00K
42.00K
255.00K
-
Effective tax rate
-0.02%
-0.15%
-0.82%
-
Other operating expenses
-
-
-
-
Net income
-200.74M
-27.78M
-31.17M
-31.99M
Net profit margin
-
-
-
-
Earnings per share
-
-0.62
-0.39
-0.40
Interest and investment income
1.00M
3.07M
4.06M
4.16M
Interest expense
-
-
-
-
Net interest expenses
1.00M
3.07M
4.06M
4.16M
Depreciation and amortization charges
-
-
-
-
EBITDA
-27.38M
-30.81M
-34.99M
-36.86M
Gain or loss from assets sale
-
-
-
-750.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps